Transcode Therapeutics Inc (RNAZ) Stock Price, Quote & News

Company Profile

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and t...

Industry: Biotechnology

Sector: Healthcare

Phone: 857-837-3099

Website: www.transcodetherapeutics.com

Address:

6 Liberty Square, Suite 2382, Boston, United States

mulaking Jul. 2 at 4:36 PM

Hi $RNAZ fam, I need some advice - Im sitting pretty at 124 shares with av price of 28.76 😄 go me for belieing I will see my moneys worth (F my L 😄) based on chatter I dont have a hooe for another 2 yrs hahah sooo my question. Is it worth averaging down now? or wait for this car crash to clear 😅

2 · Reply

51shades Jul. 1 at 11:06 PM

$RNAZ could someone please explain their patent position?

3 · Reply

Itinerant Jun. 30 at 6:44 PM

$RNAZ The cohort 4 results seem likely soon, I guess. However, that will set up an offer because they will need funds for the P2. That financing will be substantial and it will crush the stock, unless by some miracle they get some wonderful deal or partner. After that fuck job, there should be a rally I guess. The tech is strong, so it will get there, eventually. JMO

1 · Reply

ccarrera Jun. 30 at 10:01 AM

$RNAZ bought a small position last Friday. GL longs!

1 · Reply

stockboy66 Jun. 27 at 3:24 PM

$RNAZ The volume sucks with this one! Maybe this is a stock you should only check your holdings on a monthly basis. 🤷‍♂️

0 · Reply

Hovius Jun. 26 at 5:31 PM

$RNAZ You guys will just make them dilute sooner.. Stop it.

1 · Reply

Primitivetablemaker Jun. 26 at 5:22 PM

$RNAZ still holding and added this morning

0 · Reply

Pratik2024 Jun. 26 at 3:32 PM

$CURV $RNAZ $SMMT $TPET $CURV (when flying is eminent, buckle up): 1. The secondary public offering is expected to be closed today, 26 June. 2. The company is buying back shares of $20 million.

0 · Reply

51shades Jun. 25 at 2:46 PM

$RNAZ Looking for the revenue side of their business model. All the way to market? A partner acquisition? Why is there no mention of any potential partnerships in the company presentation or Q?

1 · Reply

makedatbread88 Jun. 24 at 7:39 PM

$RNAZ someone’s quietly loading this low float RS name the last week. Watching 833k float

1 · Reply

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

May 8, 2025, 8:05 AM EDT - 2 months ago

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

May 5, 2025, 5:07 PM EDT - 2 months ago

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 2, 2025, 4:10 PM EDT - 2 months ago

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 1, 2025, 9:01 AM EDT - 2 months ago

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

Apr 21, 2025, 4:37 PM EDT - 2 months ago

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

Mar 27, 2025, 4:37 PM EDT - 3 months ago

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Mar 25, 2025, 6:24 PM EDT - 3 months ago

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

Mar 23, 2025, 11:11 PM EDT - 3 months ago

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 13, 2025, 7:47 AM EDT - 4 months ago

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Feb 25, 2025, 4:15 PM EST - 4 months ago

TransCode Therapeutics, Inc. Announces Results of Special Meeting

Feb 6, 2025, 8:00 AM EST - 5 months ago

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

Jan 14, 2025, 8:00 AM EST - 6 months ago

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Jan 7, 2025, 8:00 AM EST - 6 months ago

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

Dec 18, 2024, 8:00 AM EST - 7 months ago

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Nov 29, 2024, 4:25 PM EST - 7 months ago

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

Nov 27, 2024, 7:00 AM EST - 7 months ago

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

Nov 5, 2024, 7:00 AM EST - 8 months ago

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Sep 17, 2024, 7:00 AM EDT - 10 months ago

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Sep 5, 2024, 7:00 AM EDT - 10 months ago

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

Jul 24, 2024, 4:05 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Closing of Public Offering

Jul 22, 2024, 10:30 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

Jul 22, 2024, 4:07 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

May 29, 2024, 9:15 AM EDT - 1 year ago

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

May 13, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Open Letter to Shareholders

Apr 15, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

Apr 3, 2024, 9:10 AM EDT - 1 year ago

TransCode Therapeutics Reports 2023 Results; Provides Business Update

Mar 28, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Mar 11, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

Mar 6, 2024, 4:15 PM EST - 1 year ago

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

Feb 20, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Jan 31, 2024, 4:05 PM EST - 1 year ago

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

Jan 29, 2024, 8:30 AM EST - 1 year ago

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Jan 22, 2024, 4:45 PM EST - 1 year ago

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

Jan 18, 2024, 1:27 PM EST - 1 year ago

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

Jan 12, 2024, 4:05 PM EST - 1 year ago

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

Jan 11, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Jan 4, 2024, 8:05 AM EST - 1 year ago

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

Dec 12, 2023, 8:30 AM EST - 1 year ago

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

Dec 5, 2023, 9:00 AM EST - 1 year ago

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

Dec 4, 2023, 4:10 PM EST - 1 year ago

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Nov 30, 2023, 2:53 PM EST - 1 year ago

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Nov 14, 2023, 4:30 PM EST - 1 year ago

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

Oct 30, 2023, 4:33 PM EDT - 1 year ago

TransCode Therapeutics Withdraws Public Offering

Oct 27, 2023, 8:00 AM EDT - 1 year ago

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

Oct 26, 2023, 4:19 PM EDT - 1 year ago

TransCode Therapeutics Announces Public Offering of Common Stock

Oct 26, 2023, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

Oct 24, 2023, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

Oct 16, 2023, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

Sep 28, 2023, 4:02 PM EDT - 1 year ago

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

mulaking Jul. 2 at 4:36 PM

2 · Reply

51shades Jul. 1 at 11:06 PM

$RNAZ could someone please explain their patent position?

3 · Reply

Itinerant Jun. 30 at 6:44 PM

1 · Reply

ccarrera Jun. 30 at 10:01 AM

$RNAZ bought a small position last Friday. GL longs!

1 · Reply

stockboy66 Jun. 27 at 3:24 PM

$RNAZ The volume sucks with this one! Maybe this is a stock you should only check your holdings on a monthly basis. 🤷‍♂️

0 · Reply

Hovius Jun. 26 at 5:31 PM

$RNAZ You guys will just make them dilute sooner.. Stop it.

1 · Reply

Primitivetablemaker Jun. 26 at 5:22 PM

$RNAZ still holding and added this morning

0 · Reply

Pratik2024 Jun. 26 at 3:32 PM

$CURV $RNAZ $SMMT $TPET $CURV (when flying is eminent, buckle up): 1. The secondary public offering is expected to be closed today, 26 June. 2. The company is buying back shares of $20 million.

0 · Reply

51shades Jun. 25 at 2:46 PM

$RNAZ Looking for the revenue side of their business model. All the way to market? A partner acquisition? Why is there no mention of any potential partnerships in the company presentation or Q?

1 · Reply

makedatbread88 Jun. 24 at 7:39 PM

$RNAZ someone’s quietly loading this low float RS name the last week. Watching 833k float

1 · Reply

rock_it_stocks Jun. 24 at 7:11 PM

$RNAZ Wow! Someone is buying! I didn't think that $70,000 wall would fall. 90 day lock-up expired yesterday, so I wonder if some insiders know something we don't.

0 · Reply

Scoty_D Jun. 24 at 2:40 AM

$RNAZ

0 · Reply

Abdujabbar90 Jun. 23 at 8:47 AM

$RNAZ news come

0 · Reply

Hovius Jun. 20 at 8:10 PM

$RNAZ Takes real courage, to hold this into a weekend.. God bless..

0 · Reply

Itinerant Jun. 20 at 7:55 PM

$RNAZ My short term theory about RNAZ is that they will report great cohort 4 results, and then be positioned for financing the P2. At this point they will be able to do a real financing with serious investors, without toxic warrants etc. That financing will cause a major up valuation because the technology is presently seriously under valued. JMO

2 · Reply

InstinctInvestor Jun. 20 at 4:56 PM

Wow $RNAZ YOU REALLY BROKE AELRTS HUH 🤔 OK 👌🏾

1 · Reply

bigmoneygrip9 Jun. 20 at 4:53 PM

$RNAZ why this pop

1 · Reply

InstinctInvestor Jun. 20 at 4:52 PM

Not even thinking about $RNAZ until $7.50 cross

0 · Reply

TobySquatch Jun. 20 at 12:02 PM

$RNAZ Stock stinks of ass

0 · Reply

Zeusgodmd Jun. 18 at 2:41 PM

$RNAZ maybe see tomorrow markets closed would be good with a partner

0 · Reply

YasirTrades Jun. 18 at 2:14 PM

GLMD is a ticking time bomb 💣 Trading under cash. $20+ book. No debt. Tiny float. GLP-1 catalyst loading. Chart is coiled tight. When volume hits… boom 💥 100%+ upside? That might be conservative. $ACXP, $TENX, $DRMA, $RNAZ On watch too

0 · Reply

Itinerant Jun. 18 at 12:59 PM

$RNAZ We should be about due to receive a report on cohort 4. I expect that will be an important positive event.

1 · Reply

Market Cap	7.04M
Revenue (ttm)	0.00
Net Income (ttm)	-16.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	10,658
Avg Vol	168,812
Day's Range	N/A - N/A
Shares Out	833,000.00
Stochastic %K	85%
Beta	1.40
Analysts	Strong Buy
Price Target	$10.00